Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Downregulation of PGC-1 α Prevents the Beneficial Effect of EET-Heme Oxygenase-1 on Mitochondrial Integrity and Associated Metabolic Function in Obese Mice

Singh SP., Bellner L., Vanella L., Cao J., Falck JR., Kappas A.

Animal Study on Hip, Systemic / IV, published in J Nutr Metab (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Nutr Metab (2016)
Reported sample size
—
Source database
Europe PMC
PMID
28097021
PMCID
PMC5206458
DOI
10.1155/2016/9039754
Citations
33

Abstract (original English)

Background/Objectives . Obesity and metabolic syndrome and associated adiposity are a systemic condition characterized by increased mitochondrial dysfunction, inflammation, and inhibition of antioxidant genes, HO-1, and EETs levels. We postulate that EETs attenuate adiposity by stimulating mitochondrial function and induction of HO-1 via activation of PGC-1 α in adipose and hepatic tissue. Methods . Cultured murine adipocytes and mice fed a high fat (HF) diet were used to assess the functional relationship among EETs, PGC-1 α , HO-1, and mitochondrial signaling using an EET-agonist (EET-A) and PGC-1 α -deficient cells and mice using lentiviral PGC-1 α (sh). Results . EET-A is a potent inducer of PGC-1 α , HO-1, mitochondrial biogenesis (cytochrome oxidase subunits 1 and 4 and SIRT3), fusion proteins (Mfn 1/2 and OPA1) and fission proteins (DRP1 and FIS1) ( p α (sh). EET-A administration prevented HF diet induced mitochondrial and dysfunction in adipose tissue and restored VO 2 effects that were abrogated in PGC-1 α -deficient mice. Conclusion . EET is identified as an upstream positive regulator of PGC-1 α that leads to increased HO-1, decreased BW and fasting blood glucose and increased insulin receptor phosphorylation, that is, increased insulin sensitivity and mitochondrial integrity, and possible use of EET-agonist for treatment of obesity and metabolic syndrome.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research